BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-ORIGINAL-URL:https://www.europabio.org X-WR-CALDESC:Events for Europabio REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:Europe/Brussels BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20200329T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20201025T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20210328T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20211031T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20220327T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20221030T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20230326T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20231029T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20240331T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20241027T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20250330T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20251026T010000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20241119T000000 DTEND;TZID=Europe/Brussels:20241119T235959 DTSTAMP:20260726T164841 CREATED:20241029T130646Z LAST-MODIFIED:20241030T124012Z UID:8442-1731974400-1732060799@www.europabio.org SUMMARY:SME roundtable: Towards globally competitive European SMEs DESCRIPTION:Europe is home to a vibrant community of Biotechnology SMEs contributing to the modernisation of the European industry. European biotechnology SMEs are the main drivers for innovation in healthcare\, food and feed\, industrial processes and manufacturing. \n\n\n\nThe Initiative on “Boosting Biotechnology and Biomanufacturing in the EU” published by the European Commission in March 2024 provides great prospects for EU SMEs. It highlights the EU ambition to deliver the benefits of biotechnology to support EU competitiveness and innovation alongside other global regions. One objective of the initiative is to identify ways to streamline EU legislation and its implementation to reduce Single Market fragmentation\, explore potential simplification of regulatory processes\, and shortening the time to market of biotechnological innovations. \n\n\n\nIn order to meet this objective\, EuropaBio\, the voice of biotechnology industries in Europe\, will be hosting this roundtable to work as partners with all relevant stakeholders to guarantee the success of this Initiative. This roundtable session aims to provide a discussion forum for SME participants active in the sector to share their main driving forces and obstacles to accessing global markets and supply chains. The session will explore the essential elements required to speed up EU market access of biotech products. \n\n\n\nThis event will be followed by a dedicated report exploring the sessions outcomes. \n\n\n\nFor more information\, contact: communications@europabio.org URL:https://www.europabio.org/event/sme-roundtable-towards-globally-competitive-european-smes/ CATEGORIES:EFIB,EuropaBio,SME Platform ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/10/External-Events-Banners-600-×-200px-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20241001T170000 DTEND;TZID=Europe/Brussels:20241001T200000 DTSTAMP:20260726T164841 CREATED:20240517T115325Z LAST-MODIFIED:20240517T115327Z UID:7794-1727802000-1727812800@www.europabio.org SUMMARY:Europe's Biotechnology & Biomanufacturing Future DESCRIPTION:Biotechnology is a critical technology for global economic security\, health and sustainability. \n\n\n\nEurope’s world-leading research is translated into medicines\, food and next generation biomanufacturing across sectors in all European regions\, with employment\, skills and economic growth as part of a more sustainable\, healthy\, autonomous and competitive Europe. \n\n\n\nThe importance of biotechnology to Europe is now recognised through multiple actions. The European Commission Initiative “Boosting Biotechnology and Biomanufacturing in the EU” highlights the EU ambition to deliver biotechnology for competitiveness and societal impact alongside fast moving global regions\, whilst the Letta report highlights its significance within a well-functioning single market. It is amplified further through its specific inclusion in legislations such as STEP and the Net Zero Industry Act. \n\n\n\nEuropaBio\, the voice of biotechnology industries in Europe\, will be hosting this reception to explore how biotechnology is used across sectors. Invited guests will meet the European innovators that deliver and use biotechnology and understand how it benefits the quality of life of all EU citizens. \n\n\n\nInnovative companies plus national and regional biotechnology associations will share their knowledge\, and guests will network across EU Institutions and other key stakeholders to discover how the European Union builds the future of biotechnology. \n\n\n\nFor more information\, contact: communications@europabio.org URL:https://www.europabio.org/event/europes-biotechnology-biomanufacturing-future/ CATEGORIES:Biotech Week,EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/05/Event-Banner-for-Website.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20240930T140000 DTEND;TZID=Europe/Brussels:20240930T160000 DTSTAMP:20260726T164841 CREATED:20240719T161756Z LAST-MODIFIED:20240927T055832Z UID:8081-1727704800-1727712000@www.europabio.org SUMMARY:How does a Novel Food get to your plate? DESCRIPTION:This EuropaBio’s webinar will focus on the pathway to market for Novel Foods\, from initial development in R&D through to consumer uptake while going through risk assessment and approval. Each speaker will cover a key point along the value chain\, including illustrative examples and case studies where relevant.    \n\n\n\nThe event will be moderated by Hannah Lester\, CEO at Atova Consulting. \n\n\n\nThe confirmed speakers are: \n\n\n\n\nMuriel Dewilde\, Business Development Manager\, Bio Base Europe Pilot Plant\n\n\n\nErmolaos Ververis\, Scientific Officer Nutrition & Food Innovation Unit\, EFSA\n\n\n\nTimen Van Haaster\, Public Affairs & Communications Director\, HollandBio\n\n\n\nAnders Nelving\, Line Solution Manager\, Tetra Pak\n\n\n\nPer Falholt\, CSO at 21st Bio\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\nRegister Here URL:https://www.europabio.org/event/how-does-a-novel-food-get-to-your-plate/ CATEGORIES:Biotech Week,EuropaBio ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2024/07/banner-website.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20240924T140000 DTEND;TZID=Europe/Brussels:20240924T153000 DTSTAMP:20260726T164841 CREATED:20240604T072713Z LAST-MODIFIED:20240919T083820Z UID:7902-1727186400-1727191800@www.europabio.org SUMMARY:The Future of Biotech: The Role of Legislation within Investment for Innovation DESCRIPTION:To celebrate the start of European Biotech Week 2024\, EuropaBio is organising a webinar to discuss the critical intersection of legislation and investment into innovation within the biotech industry. With clear political support for European leadership in biotech\, ensuring EU legislation become key enabler of investment for innovation will be essential to the EU’s global competitiveness and strategic open autonomy. \n\n\n\nThis webinar will bring together representatives from the biotech industry\, investor community\, and European institutions to explore the essential elements required to foster a thriving biotech and life sciences ecosystem in the EU. \n\n\n\nThe confirmed speakers and full agenda are: \n\n\n\nWelcome and introduction  \n\n\n\nMarica Nobile (Assobiotec Federchimica) \n\n\n\nKeynote speech: EU biotech & biomanufacturing initiative  \n\n\n\nHans Ingels (DG GROW) \n\n\n\nPanel: Impact of EU Legislation on Investment Opportunities  \n\n\n\nYordan Aleksandrov (Pfizer) \n\n\n\nSME – Anna Handschuh (Future Affairs) \n\n\n\nNicoló Giacomuzzi-Moore (CBEJU) \n\n\n\nKatrien Swerts (Kurma Partners) \n\n\n\nMarica Nobile (Assobiotec Federchimica) will moderate the panel and deliver closing remarks. \n\n\n\n \n\n\n\n \n\n\n\n\nRegister Here URL:https://www.europabio.org/event/the-future-of-biotech-the-role-of-legislation-on-investment-for-innovation/ CATEGORIES:Biotech Week,EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/06/GENERAL.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20240626T170000 DTEND;TZID=Europe/Brussels:20240626T190000 DTSTAMP:20260726T164841 CREATED:20240429T092024Z LAST-MODIFIED:20240513T092250Z UID:7743-1719421200-1719428400@www.europabio.org SUMMARY:NAC Belgian Presidency Summer Reception DESCRIPTION:EuropaBio\, bio.be/essenscia\, and flanders.bio biotechnology associations are organising a summer reception in Brussels for its members and invited guests to mark the end of the Belgium Council Presidency of the European Union and celebrate what best is made in Belgium – (beyond waffles and beers)\, biotechnology! \n\n\n\nWe will present the outcomes of our National Associations Council Presidency Summit “Made in Belgium for Europe“\, with recommendations on advanced therapies for rare diseases and microorganisms’ role in agricultural applications.  \n\n\n\nIf you wish for more details\, please reach out to communications@europabio.org URL:https://www.europabio.org/event/nac-belgian-presidency-summer-reception/ CATEGORIES:EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/04/Untitled-1-NAC-RECEPTION.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20240507T140000 DTEND;TZID=Europe/Brussels:20240507T150000 DTSTAMP:20260726T164841 CREATED:20240429T082059Z LAST-MODIFIED:20240429T084605Z UID:7736-1715090400-1715094000@www.europabio.org SUMMARY:Biomanufacturing Policy Summit - Report Launch DESCRIPTION:“Policy pathways for biomanufacturing in Europe” was the theme of the Biomanufacturing Policy Summit 2024. The upcoming report will summarise the Summit’s keynote speeches and panel discussions and translate them into an analysis to Europe’s biomanufacturing strengths\, weaknesses\, opportunities and threats based on specific policies and industrial examples. \n\n\n\nThe report launch will also feature speakers who will respond to the report’s main conclusions and comment on their alignment with current challenges and future goals. \n\n\n\n\nHanna Freienstein\, Policy Officer\, DG GROW – European Commission\n\n\n\n⁠Jérôme Fabiano\, Deputy Director & Corporate Affairs Director\, EIT Health France\n\n\n\n⁠Per Falholt\, Chief Science Officer\, 21st.BIO\n\n\n\n\nThe boost to biotech and biomanufacturing needs a strong knowledge-based approach and the upcoming report aims to contribute to the discussion. Do not miss the opportunity and be up to date about biomanufacturing in Europe. URL:https://www.europabio.org/event/europabios-biomanufacturing-policy-summit-report-launch/ CATEGORIES:Biomanufacturing Platform,EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/04/Untitled-600-x-200-px.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20240416T083000 DTEND;TZID=Europe/Brussels:20240416T120000 DTSTAMP:20260726T164841 CREATED:20240326T082922Z LAST-MODIFIED:20240326T083218Z UID:7614-1713256200-1713268800@www.europabio.org SUMMARY:RARE DISEASES FORUM 2024 DESCRIPTION:Against the backdrop of the Belgian EU Council Presidency\, the Rare Diseases Forum 2024 brings together senior leaders from across patient organisations\, industry and policy to address how and why innovation in tackling rare diseases can support the EU’s competitiveness agenda. \n\n\n\n \n\n\n\nAbout ‘The Rare Diseases Forum 2024: Securing Europe’s Competitiveness in R&D for people living with rare diseases’ features keynotes and panel discussions with a focus on the EU’s role in enhancing competitiveness in life sciences\, fostering investment in the rare diseases sector\, and examining the benefits of a competitive agenda for those with rare diseases.  \n\n\n\nThe event is convened by Global Counsel on behalf of the forum partners\, EURORDIS\, RaDiOrg\, EFPIA\, Eucope\, EuropaBio\, Pharma.be\, UCB\, Novo Nordisk\, Sanofi & Takeda. URL:https://www.europabio.org/event/rare-diseases-forum-2024/ CATEGORIES:EuropaBio,External,Healthcare Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/03/Event-Banner-Website-updated.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20240319T143000 DTEND;TZID=Europe/Brussels:20240319T164500 DTSTAMP:20260726T164841 CREATED:20240213T092326Z LAST-MODIFIED:20240213T093923Z UID:7402-1710858600-1710866700@www.europabio.org SUMMARY:Industrial biotech: Is Europe ready to harness its potential? DESCRIPTION:A Science | Business closed-door roundtable\, organised in partnership with EuropaBio – followed by networking reception \n\n\n\nOnly By Invitation \n\n\n\n \n\n\nBackground Information \nIn recent years industrial biotechnology – also known as “white” biotech – has emerged as a high-value driver of industrial modernisation and the green transition. Through the innovative use of microorganisms and enzymes\, it has transformative potential for manufacturing\, waste use and the creation of sustainable products in sectors as varied as energy\, textiles\, plastics\, paper\, agriculture and water. While some core processes\, such as fermentation technology\, have been commercially deployed for around 50 years\, the speed of scientific progress and solution development are accelerating exponentially. As such\, it appears that the sector as a whole is truly poised to make the leap from “proof of concept” to mainstream application at the European level. \nThese take on greater importance when one considers other strategic priorities for the EU. First\, it is clear that for Europe to achieve e.g. its 2030 benchmark for net-zero technology manufacturing in the Green Deal Industrial Plan (GDIP)\, it will need to leverage its full innovation capacity across sectors. Second\, as global demand grows for sustainable solutions to climate\, energy\, biodiversity and food system crises\, Europe is ideally positioned to take market leadership in various domains\, given its research excellence and strong industrial base. And third\, the EU’s proposed Strategic Technologies for Europe Platform (STEP) has already identified biotechnologies among its key value chains to ensure future resilience\, autonomy and competitiveness\, while biotechnology has also been recognised as a critical technology for Europe. \nYet a degree of skepticism remains – both in public and policy circles – about the risk/reward ratio of biotechnologies and their wider value to society. One useful counterpoint is to consider the evolution of health-related biotechnology (often called “red” biotech). Having overcome similar resistance and concerns\, “red” biotech is now deployed at scale throughout the life science and pharmaceutical sectors\, and is acknowledged today as a key component in European health innovation. So how can the lessons learned on that journey be absorbed and applied to other sectors? \n As the EU prepares for its transition to a new Parliament and Commission\, it is therefore an ideal moment to open a multistakeholder dialogue on how policy and regulatory innovations could increase the European added value of “white” biotech and biomanufacturing in the years to come. This also builds on Ursula von der Leyen’s announcement of a new biotech and biomanufacturing initiative in last September’s state-of-the-union address. Among some of the key issues for consideration: \nWhere can industrial biotech and biomanufacturing contribute most effectively to the GDIP and STEP\, and what are the longer-term implications for boosting the global competitiveness of European companies?\nWhat should underpin a future EU roadmap for advancing “white” biotech and biomanufacturing across sectors\, in line with other long-term strategies and objectives?\nWhich other steps are needed at EU and national level to build future capacity\, such as infrastructure and skills?\nIn which ways can public and private finance best support pioneering “white” biotech firms – large and small – in scaling up and maturing their solutions to market-readiness and mass production levels\, as has happened in the health sector?\nBeyond the CBE Joint Undertaking\, to what extent could Horizon Europe\, FP10 and other key instruments – such as the new biotech & biomanufacturing initiative – strengthen Europe’s industrial biotech R&D ecosystem in the next policy cycle?\nOn March 19\, Science|Business\, in cooperation with EuropaBio\, will convene a select group of senior figures and experts from across the industrial biotech spectrum to address these issues in a closed-door\, invitation-only roundtable. Drawing in part on latest research and real-world applications\, the meeting will identify recommendations to harness the full potential of “white” biotech and biomanufacturing\, and to align its further development with the realisation of key EU policy goals.\n \n \n\n\n\n\n\n\n \n\n\n\n \n\n\n\nFor more information\, please contact: denitsa.nikolova@sciencebusiness.ne \n\n\n\n \n\n\n\n \n\n\n\n\nClick here for more information URL:https://www.europabio.org/event/industrial-biotech-is-europe-ready-to-harness-its-potential/ CATEGORIES:EuropaBio,Industrial Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/02/Event-Banners-Website-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20240313T130000 DTEND;TZID=Europe/Brussels:20240313T200000 DTSTAMP:20260726T164841 CREATED:20231213T100000Z LAST-MODIFIED:20240209T113124Z UID:7082-1710334800-1710360000@www.europabio.org SUMMARY:Biomanufacturing Policy Summit 2024 - Policy pathways for biomanufacturing in Europe DESCRIPTION:The Biomanufacturing Policy Summit will host its 2nd edition in March 2024. The invite-only half-day summit hosted by EuropaBio brings together stakeholders including industry representatives and policymakers\, to discuss Europe’s ambitions for biomanufacturing and the tangible legislative\, regulatory and strategic pathways. \n\n\n\n2023 was a year of visibility and recognition for biomanufacturing in Europe. It saw the creation of the Strategic Technologies for Europe Platform (STEP) and the announcement of the EU Biotech and Biomanufacturing Initiative\, plus the identification of biotechnology as a critical technology for Europe’s security. 2024 is expected to be a year in which initiatives gain policy momentum\, within a new Parliament and Commission and begin to deliver practical and impactful instruments to European industries. \n\n\n\n \n\n\n\n13:00 – Lunch14:00 – Welcome & Introduction14:10 – Keynote Speakers15:30 – Defragmenting and Accelerating Europe’s Biotech & Biomanufacturing – The Role of Policy “How does policy impact decisions for biomanufacturing companies in Europe across sectors?”16:15 – Coffee Break16:30 – Out of the Box – A Global View on Biomanufacturing Policies “What can Europe learn and lead from policy across global regions?”17:15 – How does Policy deliver for Biomanufacturing – Looking Ahead “The policy future for Europe\, with recommendations for the incoming Commission and Parliament.”18:00 – Networking Reception \n\n\n\n \n\n\n\nParticipants will discuss how policy enables Europe to seize the opportunity for biomanufacturing within innovative\, sustainable and critical products within global supply chains. The Summit will address policy pathways for how biotech and biomanufacturing can deliver results in competitiveness\, Green Transition and resilience across sectors. \n\n\n\nFor all enquiries\, please contact our Biomanufacturing Platform Coordinator\, Francisco Castro Alves: f.alves@europabio.org URL:https://www.europabio.org/event/biomanufacturing-policy-summit-2024-policy-pathways-for-biomanufacturing-in-europe/ CATEGORIES:Biomanufacturing Platform,EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/12/Event-Banner-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20240307T130000 DTEND;TZID=Europe/Brussels:20240307T143000 DTSTAMP:20260726T164841 CREATED:20240209T095401Z LAST-MODIFIED:20240306T151454Z UID:7385-1709816400-1709821800@www.europabio.org SUMMARY:EuropaBio Webinar – How will the revision EU General Pharmaceutical Legislation impact Europe’s innovation ecosystem and biotechnology companies? DESCRIPTION:Join us on 7 March to discuss the impact of revision of the EU’s General Pharmaceutical Legislation (GPL) on Europe’s innovation ecosystem and biotechnology companies. \n\n\n\nFollowing the publication on 24 January 2024 of a new study analysing the expected impact of the GPL on the biotechnology innovation ecosystem\, EuropaBio is delighted to invite you to attend its exclusive webinar to discuss the consequences of this landmark legislation for the future of innovation in healthcare in Europe\, EU patients and economies within a global race towards health security and competitiveness. \n\n\n\nThe event will start with a presentation of the study by Charles Rivers Associates and will be followed by a panel discussion featuring leading voices of the European biotechnology ecosystem to discuss the impact of the proposed legislation and its consequences on the development of breakthrough medicines for EU patients. \n\n\n\nThe webinar will take place on Thursday 7 March at 13.00 CET. If you wish to attend\, please register below. \n\n\n\nAgenda: \n\n\n\n\nWelcome & Introduction: 13:00 – 13:05\, Dr Claire Skentelbery\, Director General EuropaBio\n\n\n\n\n\nReport Presentation and Q&A: 13:05 – 13:30\, Antun Sablek & Tim Wilsdon\, Charles River Associates\n\n\n\nPanel Discussion and Q&A: 13:30 – 14:25\, Panelists: John James Ricketts\, Noel Minnis\, Thomas Bols\, Tineke Van hooland\, Wojciech Nowak and Yordan Aleksandrov. Moderated by Dr Claire Skentelbery.\n\n\n\nConcluding Remarks: 14:25 – 14:30 Dr Claire Skentelbery\, Director General EuropaBio\n\n\n\n\n \n\n\n\nSpeakers: Moderated by Dr Claire Skentelbery\, EuropaBio \n\n\n\n\nAntun Sablek\, Charles River Associates\n\n\n\nJohn James Ricketts\, Eli Lilly\n\n\n\nNoel Minnis\, Takeda\n\n\n\nThomas Bols\, PTC Therapeutics\n\n\n\nTim Wilsdon\, Charles River Associates\n\n\n\nTineke Van hooland\, Bio.be\n\n\n\nWojciech Nowak\, Novartis\n\n\n\nYordan Aleksandrov\, Pfizer\n\n\n\n\n\nRegister here URL:https://www.europabio.org/event/europabio-webinar-how-will-the-revision-eu-general-pharmaceutical-legislation-impact-europes-innovation-ecosystem-and-biotechnology-companies/ CATEGORIES:EuropaBio,Healthcare Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/02/CRA-Webinar-Banner-Event-Website.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20240221T100000 DTEND;TZID=Europe/Brussels:20240221T120000 DTSTAMP:20260726T164841 CREATED:20231218T141335Z LAST-MODIFIED:20240206T094606Z UID:7206-1708509600-1708516800@www.europabio.org SUMMARY:Made in Belgium for Europe\, National Associations' Council Presidency Summit DESCRIPTION:Whether it’s microorganisms revolutionising manufacturing or advanced therapies for rare disease patients\, biotechnology is leading the way\, and Belgium is on it.  \n\n\n\nIf you are a researcher\, entrepreneur\, policy wonk\, or simply curious about the future of biotechnology\, join us in our free online conversation. \n\n\n\nThis conversation will be public and held online on February 21\, 2024\, from 10:00 to 12:00. If you wish to attend our session\, please register. If you have any questions\, insights or suggestions\, do not hesitate to contact José Peres at j.peres@europabio.org. \n\n\n\n \n\n\n\n\nRegister here\n\n\n\n\n \n\n\n\n\nDownload the Agenda URL:https://www.europabio.org/event/made-in-belgium-for-europe-national-associations-council-presidency-summit/ CATEGORIES:EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/12/Banner-Event-Website-4.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20240124T120000 DTEND;TZID=Europe/Brussels:20240124T150000 DTSTAMP:20260726T164841 CREATED:20240109T104014Z LAST-MODIFIED:20240116T095205Z UID:7234-1706097600-1706108400@www.europabio.org SUMMARY:EU pharmaceutical legislation - Europe’s biotech innovation in the balance? DESCRIPTION:Event agenda \n\n\n\n12:00: Registration opens \n\n\n\n12:30: Panel starts \n\n\n\n13:45: Panel close and networking lunch \n\n\n\n15:00: Close \n\n\n\nConfirmed Speakers \n\n\n\nTomislav Sokol MEPMember SANT Committee\, European Parliament \n\n\n\nHilde StevensCo-director\, Institute for Interdisciplinary Innovation in Healthcare (I3H)\, ULB \n\n\n\nKristin ThompsonChief Operating Officer\, eureKARE \n\n\n\nVivian TsevelekiChief Operating Officer\, theraCell \n\n\n\nMore to be announced soon \n\n\n\nIntroduction \n\n\n\nIn April 2023\, the European Commission adopted a proposal for a new Directive and a new Regulation\, aimed at revising and replacing the existing General Pharmaceutical Legislation (GPL). The proposal focuses on modernising the pharmaceutical sector with a patient-centred approach\, while also fully supporting an innovative and competitive industry. \n\n\n\nThrough the proposal\, the EU aims to offer an attractive and innovation-friendly environment for research\, development\, and production of medicines in Europe. The EU plans to create this environment by promoting world-class innovation\, governed by stable and consistent rules that keep pace with innovation and which increase competitiveness while reducing red tape and costs. \n\n\n\nOne of the sectors impacted by the proposal is that of biotechnology\, which has been instrumental in the discovery and development of therapies\, diagnostics\, vaccines and\, most importantly\, advanced medicines. These ‘next generation medicines’ are delivered through a complex and interdependent biotechnology ecosystem\, where companies of all sizes contribute to establishing a pathway to patients. \n\n\n\nJoin this Euractiv Hybrid Conference to discuss Europe’s biotech innovation in light of the EU’s reform of the General Pharmaceutical Legislation. \n\n\n\nQuestions to be discussed include: \n\n\n\n\nHow can Europe’s biotechnology industry maintain its competitiveness in the global medical market?\n\n\n\nHow can we establish a framework that fosters the growth of small biotech innovators?\n\n\n\nWhat are the reactions of investors to the challenges faced by small biotech companies\, and how do these reactions influence the trajectory of innovation in the biotech industry?\n\n\n\nWhat strategies can be employed to establish a successful innovation pathway for biotech companies\, while considering and aligning with the objectives of the reformed GPL? URL:https://www.europabio.org/event/eu-pharmaceutical-legislation-europes-biotech-innovation-in-the-balance/ CATEGORIES:All,EuropaBio,External,Healthcare Biotech,SME Platform ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/01/EuropaBio.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20231201T083000 DTEND;TZID=Europe/Brussels:20231201T094500 DTSTAMP:20260726T164841 CREATED:20231031T084455Z LAST-MODIFIED:20231031T084520Z UID:7041-1701419400-1701423900@www.europabio.org SUMMARY:EFIB 2023 Rotterdam Statement wider launch DESCRIPTION:Industrial biotechnology for a sustainable and resilient global Europe  \n\n\n\nAs the EU looks ahead to the European elections in 2024\, with a new EU Commission mandate and Work Programme\, EuropaBio reviews European strategies and ambitions where biotechnology plays a key role. Ursula von der Leyen’s State of the European Union address of 13 September announced an ‘EU Biotech and Biomanufacturing Initiative’. The announced EU initiative is the latest indication of a greater point of recognition and acceleration for biotechnology. \n\n\n\nBuilding on this momentum\, the EFIB Rotterdam Statement of 2023 provides a priority pathway for biotechnology to support Europe’s global leadership\, resilience and competitiveness. \n\n\n\nWe invite you to join us for a discussion on the role and potential of biotechnology and Europe’s global position in the context of the 2024 EU election. \n\n\n\n\nInvitation Only Event URL:https://www.europabio.org/event/efib-2023-rotterdam-statement-wider-launch/ CATEGORIES:EFIB,EuropaBio,Industrial Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Vilnius-Statement-Event-600-×-260px.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20231130T143000 DTEND;TZID=Europe/Brussels:20231130T160000 DTSTAMP:20260726T164841 CREATED:20231018T092656Z LAST-MODIFIED:20231018T113625Z UID:7003-1701354600-1701360000@www.europabio.org SUMMARY:EuropaBio Patient BioForum 2023 Roundtable on Advancing Solutions for Unmet Medical Needs DESCRIPTION:Hybrid Event | Invitation Only \n\n\n\n\n\nEuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific\, regulatory\, and policy issues between patient organisations and the biopharmaceutical industry. \n\n\n\nIn recent years\, unmet medical needs have been at the core of Europe’s pharmaceutical and public health policies. To address unmet medical needs (UMN)\, the Commission proposed as part of the revision of the EU General Pharmaceutical Legislation (GPL) to introduce a definition of UMN and a definition of high UMN. Under the Commission’s proposals\, all orphan products would qualify as addressing UMN but only a subset of products would meet the HUMN criteria. The Commission’s proposals on UMN and especially HUMN received mixed reactions from patient organisations and negative reactions from the industry. \n\n\n\nOn 1 December 2022\, EuropaBio organised a Patient BioForum which brought together industry and patient organisations to discuss the topic of UMN in view of reaching a common understanding on UMN. Those discussions revealed shared interests and concerns with the possible approach to UMN in the EU Pharmaceutical Legislation. The discussions were followed by a report which outlined recommendations to policymakers to enable Europe to address the challenge of UMN. \n\n\n\nWith the proposals now presented and being negotiated by the European Parliament and the Council\, the 2023 Patient BioForum is an opportunity to build on the 2022 Patient BioForum to foster exchanges between patient groups and industry on UMNs\, including expectations from the legislation and beyond. The 2023 Patient BioForum will also be an opportunity to issue multi-stakeholder recommendations to policymakers to ensure the GPL is fit for purpose to address patients need and support innovation.   \n\n\n\n \n\n\n\nProgramme \n\n\n\nThe 2023 Patient BioForum will be held in a roundtable format under Chatham House Rule. A wide range of stakeholders representing patients\, regulators\, policy-makers\, and industry will be invited to take part in the roundtable. All participants will be invited to take an active part in the discussion to bring their unique perspective. The roundtable will be followed by a report to summarise the discussions. \n\n\n\n1. Introductions \n\n\n\n2. Legislating Unmet Medical Needs: Perspectives from the European Commission and the European Parliament \n\n\n\n3. Roundtable topic 1: How Can the EU Pharmaceutical Legislation Help Stimulate Patient-Centric Innovation? \n\n\n\n4. Roundtable topic 2: How can Europe Incentivise R&D for UMN and Underserved Areas? \n\n\n\n5. Conclusions \n\n\n\nIf you would like to attend\, please contact Adrian Lincoln\, a.lincoln@europabio.org URL:https://www.europabio.org/event/europabio-patient-bioforum-2023-roundtable-on-advancing-solutions-for-unmet-medical-needs/ CATEGORIES:EuropaBio,Healthcare Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Event-Banners-Website-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20231024T080000 DTEND;TZID=Europe/Brussels:20231025T170000 DTSTAMP:20260726T164841 CREATED:20230413T124141Z LAST-MODIFIED:20230525T155522Z UID:6110-1698134400-1698253200@www.europabio.org SUMMARY:EFIB 2023 - Industrial biotechnology for a sustainable and resilient global Europe DESCRIPTION:EuropaBio is pleased to announce that this year’s edition of EFIB\, Europe’s Leading Event on Industrial Biotechnology and the Bioeconomy under the title ‘Industrial biotechnology for a sustainable and resilient global Europe’\, will take place 24-25 October 2023 in Rotterdam\, The Netherlands. EuropaBio is partnering with local hosts HollandBio and ChemistryNL to bring EFIB 2023 to Rotterdam. \n\n\n\nNow in its 16th year\, EFIB will be dedicated to exploring how industrial biotechnology and the bioeconomy supports European competitiveness. EFIB brings together professionals from across the value chain to discuss advancements from industrial biotechnology and its contribution towards positioning Europe as a global leader in addressing societal and sustainability challenges. Participants include industry of all sizes\, as well as the community that enables industry to deliver\, including researchers\, policy makers\, regulators\, and global organisations. \n\n\n\nOur two-day programme includes inspiring plenaries\, a start-up pitching hour and will explore our four thematic areas – Food\, Feed & Nutrition; Sustainable Biomaterials; Bioprocesses & Technologies; and Sustainable Finance – as well as new frontiers like biomanufacturing. The programme is complemented by the exhibition: including start-ups and SMEs in our SME Village\, the academic poster presentation in our Innovation Campus\, and exhibitors from industry and national associations. Interested in exhibiting? Check out our sponsorship page.   \n\n\n\nAttending EFIB 2023 will allow you to learn about the latest market trends and research findings in industrial biotechnology and network with key stakeholders. \n\n\n\n\nRegister Here\n\n\n\n\nFor more information visit our website and subscribe to our newsletter. URL:https://www.europabio.org/event/efib-2023-industrial-biotechnology-for-a-sustainable-and-resilient-global-europe/ CATEGORIES:EFIB ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/04/Copy-of-General-template-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20231011T133000 DTEND;TZID=Europe/Brussels:20231011T150000 DTSTAMP:20260726T164841 CREATED:20230920T110911Z LAST-MODIFIED:20230920T110912Z UID:6861-1697031000-1697036400@www.europabio.org SUMMARY:SMEs in a Changing World: The Impact of the Revision of the Pharmaceutical Legislation on Europe’s innovative SMEs DESCRIPTION:In April 2023\, the European Commission published new legislative proposals to revise the EU’s long-standing pharmaceutical legislation and ensure it can meet the challenges of the 21st century. The revision will redefine the regulatory framework for medicines and have a significant impact on the global innovation ecosystem. \n\n\n\nAs emerging and small companies have become innovation drivers\, responsible for over two-thirds of the R&D pipeline that will become the medicines of tomorrow\, changing the rule book that has helped build Europe’s small company ecosystem over the last 20 years is going to have consequences for start-ups\, emerging and small companies looking to first enter the market but also on mid-size companies looking for growth opportunities in Europe. \n\n\n\nThis event will be an opportunity to highlight the role of small and mid-size companies in developing medicines for patients\, assess the foreseeable impacts of the revision on those companies\, and hear directly from them what they need from the revision to continue their journey in Europe. URL:https://www.europabio.org/event/smes-in-a-changing-world-the-impact-of-the-revision-of-the-pharmaceutical-legislation-on-europes-innovative-smes/ CATEGORIES:EuropaBio,External,Healthcare Biotech,SME Platform ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/09/Event-Banners-Website.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230627T180000 DTEND;TZID=Europe/Brussels:20230627T200000 DTSTAMP:20260726T164841 CREATED:20230524T142640Z LAST-MODIFIED:20230616T172415Z UID:6330-1687888800-1687896000@www.europabio.org SUMMARY:NAC Spanish Presidency Summer Reception DESCRIPTION:EuropaBio\, and AseBio\, the Spanish Association of Biotechnology Companies\, with the support of Merck\, will host a summer reception to mark the beginning of the Spanish Council Presidency of the European Union and present the outcomes of their National Association Council Presidency Summit.  \n\n\n\nThe event will take place on June 27th in Brussels at Comet Meetings – Louise\, from 18-20h. If you wish for more details\, please get in touch with José Peres at j.peres@europabio.org  URL:https://www.europabio.org/event/nac-spanish-presidency-summer-reception/ CATEGORIES:EuropaBio ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/NAC-Summer-Reception-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230605T173000 DTEND;TZID=Europe/Brussels:20230605T183000 DTSTAMP:20260726T164841 CREATED:20230523T115247Z LAST-MODIFIED:20230524T142835Z UID:6282-1685986200-1685989800@www.europabio.org SUMMARY:EuropaBio: BIO 2023 DESCRIPTION:Round table –Biomanufacturing for health: advancing healthcare and global preparedness \n\n\n\n\n\nEuropaBio is pleased to host a round table discussion at the upcoming BIO International Convention in Boston and invites all delegates to join us to discuss on biomanufacturing for health: advancing healthcare and global prepareness. \n\n\n\nBiomanufacturing within healthcare represents an advance in therapeutic capabilities\, as ground-breaking research translates into increased diseases that can be targeted\, either for the first time or with greater efficacy\, with increasingly complex interventions becoming possible. It also brings resilience and increased environmental sustainability to strained supply chains as the world strives to modernise production systems. \n\n\n\nThe transition has significant implications for global healthcare\, competitiveness\, sustainability and resilience\, with capacity building important in all regions. \n\n\n\nThis is not just reflected in advancing healthcare for citizens but also for the world’s ability to respond to healthcare crises.  Covid demonstrated that  biomanufacturing capacity globally was called into action from multiple applications and countries for the complex manufacturing process behind vaccines. \n\n\n\nThis biomanufacturing capacity does not exist within a vacuum\, ready to be called to action when needed. It requires drug developers large and small\, public and private\, specialised manufacturers\, plus skills base\, supply chain and logistics frameworks resulting from significant investment over many years. \n\n\n\nImportantly\, a sustainable biomanufacturing framework is financed and delivered primarily through industry\, meaning that is must be integral to company strategy. This is not a guarantee\, as the global healthcare industry reacts to legislative changes and government strategies\, with major investment decisions having long term implications for the capacity and skills base within countries and regions. \n\n\n\nWhat does the world need to get right to ensure that biomanufacturing capacity grows\, to serve patients with advancing therapies and be there for coordinated emergency responses? \n\n\n\nParticipants within the round table reflect global biomanufacturing stakeholders and will discuss: \n\n\n\n\nNational policies\, incentives and strategy\n\n\n\nRegulatory and standards and alignment\n\n\n\nInternational cooperation and development\n\n\n\n\nThe output from this roundtable will be a call to global action for biomanufacturing published through EuropaBio and BIO\, with all delegates invited to contribute through the round table and follow up. \n\n\n\nAgenda \n\n\n\n10:30Welcome and introductionEuropaBio and BIO10:40Setting the scene for global biomanufacturing and the planned outcome from the round tableClaire10:45(draft) Discussion points for participants: – What does your country need to achieve for resilience through national or accessible biomanufacturing capacity?– How are regulatory frameworks adapting to an increasingly biological pipeline of medicines?– What does international cooperation need to achieve to ensure that manufacturing is actually possible during pandemic responses?– Name a priority for you to reach biomanufacturing goals in the coming years.All participants: Lead interventions on specific topics11:30Closing remarksEuropaBio and BIO\n\n\n\n\n\n\n\n \n\n\n\n\nMore information here URL:https://www.europabio.org/event/europabio-bio-2023/ LOCATION:Boston Convention & Exhibition Center\, Boston\, Massachusetts\, United States CATEGORIES:EuropaBio ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/Event-Banners-Website.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230427T140000 DTEND;TZID=Europe/Brussels:20230427T151500 DTSTAMP:20260726T164841 CREATED:20230322T114230Z LAST-MODIFIED:20230412T135959Z UID:6092-1682604000-1682608500@www.europabio.org SUMMARY:EuropaBio Biomanufacturing Policy Summit 2023: Where next for Europe? DESCRIPTION:Summit outcomes and next steps \n\n\n\n\n\nOn 15th March\, EuropaBio hosted its first Biomanufacturing Policy Summit in Brussels\, with the aim of setting the vision for Europe’s global innovation\, competitiveness\, and sustainability on biomanufacturing\, while raising awareness among policy-makers. The Summit established a starting point\, a first step for a long journey that needs to be traveled by all stakeholders in Europe – SMEs\, large companies\, expert services\, and EU institutions – and which has already started in other parts of the world. \n\n\n\n80 attendees from industry\, national associations\, and stakeholders across the public and private spectrum presented\, debated\, and proposed.  In a fast-moving industrial transition\, calls for visionary policies\, enabling regulation\, and urgent action were some of the key takeaways from the summit. You can see the March 15th Summit agenda here. \n\n\n\nWould you like to find out more? \n\n\n\nJoin us on April 27 between 14:00 – 15:15 CET for a summit presentation and follow-up and add your voice to the discussion. This webinar will wrap up the main outcomes of the summit and lay the groundwork for future discussions. \n\n\n\nBiomanufacturing is key to the digital and green transitions and to securing a competitive and resilient future for Europe. Stay tuned for Europe’s future in biomanufacturing! \n\n\n\nAGENDA\n\n\n\n14:00: Welcome and introduction – Claire Skentelbery\, Director General\, EuropaBio \n\n\n\n14:10: Biomanufacturing Policy Summit report presentation – Virginia Claudio\, Sr Adviser & Programme Manager\, EuropaBio \n\n\n\nThe report presentation summarises the summit outcomes and builds policy recommendations for the development of the Biomanufacturing landscape in Europe. \n\n\n\n14:20: Report perspectives & reflections from healthcare and biotech industries\, and national associations – Sarah Moundir\, EU Public Affairs Senior Manager\, Novartis | Gwenael Servant\, Board Executive\, Abolis | Inga Matijosyte\, Vice President\, LithuaniaBIO \n\n\n\nA diverse group of stakeholders representing the wide spectrum of Biomanufacturing shares their views over the report outcomes\, as well as the priorities for their companies and organisations. \n\n\n\n14:50: Discussion and Q&A with the audience \n\n\n\nA discussion based on questions from the audience with a focus on the next steps for policy making on Biomanufacturing. \n\n\n\n15:10: Close – Closing remarks. \n\n\n\n\n\n\nRegister Here URL:https://www.europabio.org/event/europabio-biomanufacturing-policy-summit-2023-where-next-for-europe/ CATEGORIES:Biomanufacturing Platform,EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/SM1-Quotes-Key-Messages-600-×-200px-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230418T150000 DTEND;TZID=Europe/Brussels:20230418T160000 DTSTAMP:20260726T164841 CREATED:20230124T170639Z LAST-MODIFIED:20230406T134218Z UID:5708-1681830000-1681833600@www.europabio.org SUMMARY:Development of Orphan Biologics: Challenges and Opportunities DESCRIPTION:Webinar sponsored by Catalent \n\n\n\n\n\n\n\n\n\nThe development of therapies for rare diseases comes with distinct challenges\, including patient recruitment\, setting meaningful clinical endpoints\, manufacturing and supply and finding the regulatory and market pathway to ensure patients can access therapy. \n\n\n\nFor biologic products (growth factors\, monoclonal antibodies\, other complex proteins)\, development and production costs tend to be higher due to the complexity of the drug substance. To manage costs\, the clinical development and manufacturing and Chemistry\, Manufacturing and Controls (CMC) teams need to be aligned to ensure drug product is delivered on time to meet clinical trial needs. \n\n\n\nThese challenges sit within a wider regulatory and legislative framework for orphan medicinal products (OMPs) that defines whether companies can successfully develop a novel product to market and thus the decisions made for selecting therapeutics and target diseases early in development. \n\n\n\nDuring this webinar\, speakers cover aspects of clinical trial design for orphan biologics products\, key strategies for ensuring clinical trial supply throughout clinical development and the regulatory and legislative framework for delivery to patients.Key Learning Objectives \n\n\n\n\nConsiderations in identifying meaningful clinical endpoints for orphan diseases\n\n\n\nOrphan clinical trial design considerations and strategies to ensure sufficient patient recruitment\n\n\n\nManufacturing and clinical supply strategies to ensure supply of clinical trial materials while collecting data needed to support NDA submission\n\n\n\nRegulatory and legislative frameworks that guide decision making for innovation in rare diseases\n\n\n\n\nAgenda \n\n\n\n15:00: Welcome and introduction – Claire Skentelbery\, Director General EuropaBio \n\n\n\n15:05: Current Development of Orphan Drugs in Europe – Matthias Schoenermark\, Professor\, President and CEO\, SKC Beratungsgesellschaft mbH \n\n\n\nProf. Schönermark opens the session with an overview of the current status of orphan drug development in the EU. He discusses the main challenges for market entry of new orphan drugs into the EU market and highlights key recommendations to drug developers to address these challenges. \n\n\n\n15:20: Orphan Biologics and CGT Development – CMC and Clinical Trial Supply Considerations – Wai Lam Ling\, Ph.D.\, Vice President\, Science and Technology\,  Catalent \n\n\n\nDr. Ling discusses the difference in CMC challenges encountered during an orphan biologics vs CGT programme\, with a focus on product quality as the most significant hurdle to approval. She addresses manufacturing approaches to ensure regulatory compliance and factors behind a successful product\, particularly robust\, reproducible and cost-effective pathways. Finally\, supply chain liabilities are discussed\, with risks to production of biologics and their clinical supply. \n\n\n\n15:45: Successful Strategies and Business Model For Companies Bringing Their Orphan Drug To Market –Thomas Bols\, Head of Government Affairs and Patient Advocacy\, EMEA & APAC\, PTC Therapeutics \n\n\n\nThomas Bols addresses the spectrum of opportunities and barriers for innovation within orphan drug development\, particularly across different regulatory territories\, and the critical role of smaller companies in addressing unmet medical needs. He focuses on the legislative and regulatory pathways that exist in Europe for orphan drugs and the potential impact of the upcoming pharmaceutical and OMP legislation revisions for company innovation and patient benefits. \n\n\n\n16:00: Close \n\n\n\n\nRegister here URL:https://www.europabio.org/event/development-of-orphan-biologics-challenges-and-opportunities/ LOCATION:Catalent CATEGORIES:EuropaBio,External,Healthcare Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/Biomanufacturing-Policy-Summit-2023-5.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230315T130000 DTEND;TZID=Europe/Brussels:20230315T190000 DTSTAMP:20260726T164841 CREATED:20221114T094047Z LAST-MODIFIED:20230308T114450Z UID:5505-1678885200-1678906800@www.europabio.org SUMMARY:Biomanufacturing Platform - Policy Summit 2023 DESCRIPTION:EuropaBio’s first Biomanufacturing Policy Summit will set the vision for Europe’s global innovation\, competitiveness and sustainability through the lens of biomanufacturing and set a baseline for its understanding and recognition within policy. \n\n\n\nThe half day meeting will bring together Members and invited stakeholders from across the policy\, finance\, trade\, skills and regulatory spectrum surrounding biomanufacturing. \n\n\n\nDiscussion will address what biomanufacturing looks like across sectors and the roles played by SMEs\, large companies and expert services. The economic and skills footprint will be reviewed\, plus how it sits within Europe’s twin pillars of green and digital transition within the industrial strategy. Finally\, it can start to address how policy shapes and facilitates biomanufacture and Europe’s global position for such a transformative technology in action. \n\n\n\nFrom the first Summit\, a roadmap for biomanufacture can be developed for Europe and creation of a long term discussion platform for stakeholders through the Platform. \n\n\n\nAgenda \n\n\n\n14:00Opening plenary14:00Welcome and introduction to the Biomanufacturing Policy Summit– Claire Skentelbery\, Director General\, EuropaBio14:10Biomanufacturing in Europe’s industrial transition– Peter Dröll\, Director Prosperity\, European Commission\, DG Research and Innovation14:30Biomanufacturing as a global transition: US Executive Order for Biomanufacturing in focus– Hilary Stiss\, Director\, International Affairs\, Biotechnology Innovation Organization (BIO) 14:45Quo vadis European Biomanufacturing innovation in a competitive\, globalized world– Wojciech Nowak\, Global Senior Director\, Novartis15:00I am Biomanufacturing: examples in action ● Resilience\, sustainability and competitiveness: Biomanufacturing in daily life: Ute Schick\, Senior Vice President Research\, Development and Innovation (RDI)\, Nutrition & Care (NC-RDI)\, Evonik Operations GmbH ● Growing SMEs: Biomanufacturing in the next generation of industry: Jeroen Hofenk\, Founder and Chief Science Officer\, SwiftPharma ● The national landscape: Belgium’s economic development through biomanufacturing: Tineke Van hooland\, Deputy Secretary General Bio.be ● Advanced healthcare: The role of biomanufacturing in reaching rare diseases: Philippe Moyen\, VP\, Chief of Staff to CTOO and Head of CMC Program Management – Technical Operations\, PTC Therapeutics15:30Break16:00Parallel Breakout discussionsBreakout 1 – Advanced healthcare: Role and growth in Europe● Role in Europe’s pandemic response. Scale and flexibility of manufacture – planning\, delivering\, investment● Patient access to advanced therapies (including rare diseases).● Competitiveness and economic contributor across EuropeBreakout 2 – Resilience\, competitiveness and sustainability:● Transition of industrial process for sustainability● Building resilience of supply● Innovation for competitiveness17:10Closing plenaryClosing panel discussion: Europe’s ambition and pathway for biomanufacturingStakeholders from across the biomanufacturing landscape look at the future for Europe within biomanufacturing. The industrial goals it must achieve\, the pathway towards those goals and how it can make use of the skills\, infrastructure and policy/regulatory frameworks through which Europe develops.Moderator: Kristin Schreiber (Director DG GROW)Panelists: Peter Wehrheim (Head of Unit RTD.B2)\, Kristin Thompson (COO EUREKARE)\, Nessa Fennelly (Senior Executive IBEC)\, Nicolo Giacomuzzi-Moore (Executive Director CBE JU)\, Stefaan Fiers (Head of Corporate Communication\, Public Affairs and Patient Advocacy Takeda Belgium).18:00Networking reception19:00Close\n\n\n\n \n\n\n\nSpeakers \n\n\n\n\n\n\n\n\n\n\nHilary Stiss\n\n\n\nDirector\, International Affairs\, BIO Program Director\, ICBA \n\n\n\nAs a Director for International Affairs at the Biotechnology Innovation Organization (BIO)\, Hilary is responsible for managing the industry association’s program of international advocacy and outreach for multilateral organizations. Hilary also manages the association’s engagement in Europe\, the Middle East\, North Africa\, Turkey and South Africa regions. In this position\, she engages with foreign officials in these regions to promote policies that support a strong biotechnology industry as well as to resolve policy issues relevant to the industry. Hilary also acts as Program Director for the International Council on Biotechnology Associations (ICBA). \n\n\n\n\n\n\n\n\n\n\n\n\n\nClaire Skentelbery\n\n\n\nClaire holds a PhD in biochemistry and has worked in the development of scientific networks and associations for over 15 years. She started her career as part of the Cambridge biotech cluster in the UK within the cluster business network and was a founder of the Council of European BioRegions\, a network of biotech clusters across Europe. She brought herself and CEBR to Brussels in 2009 where she also took on the role of SG for the European Biotechnology Network\, working across sectors\, organisations and countries as part of the EBN mission to facilitate partnerships. In January 2017\, Claire took up her role as DG of the Nanotechnology Industries Association which she successfully led until recently. \n\n\n\n\n\n\n\n\n\n\n\n\n\nDr. Ute Schick\n\n\n\nSenior Vice President Research\, Development and Innovation\, Evonik \n\n\n\nDr. Schick has a 20-year track record in global profit and loss responsibility at CEO and Senior Manager level within Food\, Health\, Cosmetic Industry and Material Science. Before her current role with Evonik\, she held roles as SVP of Supply Chain and Business Processes and VP of new Growth Business. Prior to working at Evonik she held roles at DuPont and DSM. \n\n\n\n\n\n\n\n\n\n\n\n\n\nWojciech Nowak\n\n\n\nGroup Senior Director\, Global Governmental and Public Affairs\, Novartis International\, Switzerland.(Functional responsibility for ca. 30 countries incl. Western & Eastern Europe\, Central Asia). \n\n\n\nMulticultural\, inclusive and reflective leader who lived in 6 countries on 3 continents.Robust understanding of the global healthcare policies and life-sciences business with more than 20 years of experience in policy creation related to healthcare systems\, EU integration and global pharmaceutical market. \n\n\n\nStarted his career at the Ministry of Health (Poland) counselling policy leaders on European integration and healthcare matters\, followed by assignments in the Ministry of Health and Solidarity of the Republic of France (Paris\, France) and Health Directorate of the European Commission (DG SANCO\, Luxembourg). \n\n\n\nAfter joining private sector has been serving in a number of senior leadership roles of growingresponsibility in healthcare companies(GlaxoSmithKline\, Abbott\, Novartis) on country\, regional and global levels (Poland\, Belgium\, Switzerland). \n\n\n\nEducated in Poland\, United States\, Nederlands\, Switzerland\, with the background in political sciences\, international relations (Warsaw’s University\, Poland; European Institute of Public Administration\, Maastricht\, Nederlands) and business administration (IMD Business School Lausanne\, Switzerland) he is an expert in healthcare systems\, global healthcare policies and international business. \n\n\n\nPassionate about delivering access and best healthcare outcomes to patients around the World. \n\n\n\n\n\n\n\n\n\n\n\n\n\nTineke Van Hooland\n\n\n\nDeputy Secretary general of bio.be/essenscia \n\n\n\nTineke Van Hooland is Deputy Secretary general of bio.be/essenscia\, the Belgian federation of companies active in life sciences & biotechnologies. She’s also a board member at EuropaBio\, the European Association for Bioindustries\, from which she also chairs the NAC\, National Associations Council. Prior to this\, Tineke held several leadership positions in biopharmaceutical companies at the corporate level over the past years. She has in-depth expertise in Governmental Affairs\, Market Access\, Communication and Patient Advocacy. Tineke graduated with High Distinction as Industrial Pharmacist from Ghent University in 2003. \n\n\n\nTineke is also the founder and CEO of epic 10\, a boutique external affairs consultancy firm\, and a respected board member in various other organizations.  She is known for her dynamic and no-nonsense approach\, is a female leadership advocate and has authored a number of opinion pieces on sustainable health policy and empowering women. \n\n\n\n\n\n\n\n\n\n\n\n\n\nKristin Schreiber\n\n\n\nKristin Schreiber leads the Directorate Ecosystems I: Chemicals\, Food\, Retail\, Health in DG GROW\, the Directorate General for Internal Market\, Industry\, Entrepreneurship and SMEs. \n\n\n\nPrior to her current Director position\, she served as Director for Governance of the Single Market and International Affairs in DG MARKT (until 2015) and Director for SME policy in DG GROW (until March 2021). \n\n\n\nKristin Schreiber was Head of Cabinet of Employment Commissioner Vladimir Špidla\, Deputy Head of Cabinet of Internal Market Commissioner Michel Barnier and member of the Cabinets of Enlargement Commissioner Günter Verheugen and Competition Commissioner Karel Van Miert. She also served as Head of Unit for International Affairs in DG Employment and Social Affairs and was a member of the Merger Task Force of DG Competition. \n\n\n\n\n\n\n\n\n\n\n\n\n\nStefaan Fiers\n\n\n\nCorporate Communications\, Public Affairs and Patient Advocacy Takeda \n\n\n\nStefaan is Head of Corporate Communications\, Public Affairs and Patient Advocacy at Takeda Belgium\, one of the largest pharmaceutical companies in Belgium. With his team\, he secures the healthcare policy analysis\, engages with external stakeholders and coordinates the company’s communication strategy. Additionally\, he oversees Takeda’s public affairs activities in 24 mid-sized European countries. \n\n\n\nBefore joining Takeda in June 2020\, he was Director of Communications and Public Policy at the Belgian pharma industry association pharma.be and held public policy positions in the pharma industry\, at Bristol-Myers Squibb Belgium/Luxembourg and at MSD Belgium.Next to his activities at Takeda\, Stefaan is an Associate Professor in Public Affairs and Comparative Politics at KU Leuven\, a Board member of PACE (Public Affairs Community Europe)\, and the author of several books and peer-reviewed articles. \n\n\n\n\n\n\n\n\n\n\n\n\n\nPhilippe Moyen\n\n\n\nVP\, Chief of Staff to CTOO and Head of CMC Program Management – Technical Operations\, PTC Therapeutics \n\n\n\nFollowing a university focus on therapeutic systems\, followed by formulation and industrial development\, Philippe has worked across the biotechnology spectrum including Baxter Healthcare\, Fresenius Kabi\, Stallergenes Greer\, and PTC Therapeutics where he has a strong focus on operations. \n\n\n\n\n\n\n\n\n\n\n\n\n\nKristin Thompson\n\n\n\nVP\, Chief Business Officer \n\n\n\nKristin Thompson is a former head of strategic partnerships in microbiomes at Bioaster. Before that\, Dr. Thompson was senior BD manager at Famar and BD manager of the French biotech company DaVolterra. She worked in research at French INSERM and the University of North Carolina\, Chapel Hill. She holds a Ph.D. in molecular biology from the University of Ulm\, Germany. \n\n\n\n\n\n\n\n\n\n\n\n\n\nNicoló Giacomuzzi-Moore\n\n\n\nExecutive Director ad interim\, Circular Bio-based Industries Joint Undertaking \n\n\n\nNicoló Giacomuzzi-Moore is CBE JU’s Executive Director ad interim and Head of the Administration and Finance Unit. He has been working in European affairs for more than 20 years\, focusing on research and innovation policy\, program implementation\, and enterprise support. \n\n\n\nBefore joining BBI JU (now CBE JU) in 2016\, he worked for the European Commission’s Research Executive Agency\, where he was responsible for financial and legal support in implementing European research projects. \n\n\n\nNicoló also worked for an Italian business association dealing with industrial policy and stakeholder management at the EU level. He holds a degree in economics and international trade. \n\n\n\n\n\n\n\n\n\n\n\n\n\nPeter Dröll\n\n\n\nDirector for Prosperity\, Directorate-General for Research and Innovation \n\n\n\nPeter Dröll has been working in the European Commission for more than 20 years with positions in the environment\, enlargement negotiations\, industry policy\, innovation\, and research. He was a Cabinet member of Enlargement Commissioner Günter Verheugen and Head of Cabinet of the Science and Research Commissioner Janez Potočnik. \n\n\n\nSince 2010 he is at the Directorate-General of Research and Innovation where he was first responsible for Innovation and then for Industrial Technologies. Following the re-orientation of DG Research and Innovation towards sustainability\, his competencies have been enlarged to include industrial R&I agendas and business intelligence as well as knowledge valorization policies. \n\n\n\nBefore joining the European Commission in 1991\, Peter worked as a lawyer in a German law firm. Peter is a lawyer by training with a doctorate degree in German constitutional law and European law. \n\n\n\n\n\n\n\n\n\n\n\n\n\nJeroen Hofenk\n\n\n\nFounder and Chief Science Officer\, SwiftPharma \n\n\n\nJeroen is a serial entrepreneur and scientist with a background in bioengineering and genetics. He has broad experience in CRISPR engineering and various expression platforms including microbial-\, animal cell-based\, and plants.  In the last 10 years of his career\, Jeroen has built a strong track record in plant-made-pharmaceutical manufacturing and the optimization thereof. He obtained 3 patent grants and holds 13 pending patents to his name.” \n\n\n\n\n\n\n\n\n\n\n\n\n\nPeter Wehrheim\n\n\n\nHead of the Unit for the “Bioeconomy and Food System” within the Directorate General for Research and Innovation of the European Commission in Brussels \n\n\n\nWhile working for Phil Hogan\, Commissioner for Agriculture and Rural Development\, he contributed to the EU Bioeconomy Strategy. From 2010 to 2018 he was Head of the Unit for Land Use and Climate Finance in DG Climate Action. Before 2004 Peter worked at the Universities of Bonn/DE\, Maryland/US (with a Heisenberg scholarship from the German Research Foundation)\, and Kiel/DE. He received his doctoral degree in agricultural economics from the University of Giessen\, Germany \n\n\n\n\n\n\nAbout the EuropaBio Biomanufacturing Platform \n\n\n\nThe Platform has the mission to represent biomanufacturing at the highest policy levels in Europe\, to ensure that it is visible and recognised within the industrial strategy and Europe’s green and digital transitions. \n\n\n\nEuropaBio’s Biomanufacturing Platform will address the policy and wider frameworks through which biomanufacturing is delivered.  Together with members and stakeholders\, it will address how economic growth\, employment and resilience are achieved through policy\, legal frameworks and regulation at EU and national levels. \n\n\n\nThe Summit will be open to EuropaBio Members and invited stakeholders. Please contact c.skentelbery@europabio.org for further information. URL:https://www.europabio.org/event/biomanufacturing-platform-policy-summit-2023/ LOCATION:BIP Meeting Center – House of the Capital Region\, rue Royale 2-4\, Brussels\, 1000\, Belgium CATEGORIES:Biomanufacturing Platform,EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/11/SM1-Quotes-Key-Messages-600-×-200px.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20221201T143000 DTEND;TZID=Europe/Brussels:20221201T160000 DTSTAMP:20260726T164841 CREATED:20221117T151753Z LAST-MODIFIED:20221121T110237Z UID:5532-1669905000-1669910400@www.europabio.org SUMMARY:EuropaBio Patient BioForum 2022: Toward a Common Understanding of Unmet Medical Needs DESCRIPTION:EuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific\, regulatory\, and policy issues between patient organisations and the biopharmaceutical industry. \n\n\n\nIn recent years\, unmet medical needs have been at the core of Europe’s pharmaceutical and public health policies. Addressing unmet medical need was outline as a central to the 2020 Pharmaceutical Strategy for Europe. One perceived shortcoming of the current legislative frameworks is insufficient stimulated development in some areas of ‘unmet medical need’ (UMN) such as antimicrobial resistance or rare diseases. The upcoming revision of the EU pharmaceutical legislation and orphan and paediatric legislation will aim at addressing “unmet medical needs”. \n\n\n\nA major hurdle to overcome is reaching a common understanding of unmet medical needs as stakeholders have different understanding of the concept based on different perceptions and expectations. Unmet medical need is scientific concept which can be used to identify patient and societal health needs and stimulate research activities. As science progresses\, and with it the knowledge to address unmet medical needs\, these needs will evolve over time from improving mortality\, modifying disease progression\, improving quality of life\, burden of the disease\, and potentially curing. \n\n\n\nBringing together multiple stakeholder groups\, including patients and industry\, the 2022 Patient BioForum is an opportunity to listen to patients’ understandings and experiences with unmet medical needs and facilitate progress towards a common understanding on unmet medical needs. \n\n\n\n \n\n\n\nSpeakers \n\n\n\n\nJoelle Khraiche\, EuropaBio\, Patient BioForum co-chair\n\n\n\n\n\nAnca Toma\, EPF\, Patient BioForum co-chair\n\n\n\n\n\nTobias S. Hagedorn\, Secretary of European Society for Phenylketonuria (ESPKU) and Managing Director of DIG PKU Germany\n\n\n\n\n\nPedro Franco\, Director Europe for Global Regulatory & Scientific Policy at Merck and Chair of EuropaBio’s OMP WG\n\n\n\n\nModerator \n\n\n\n\nAdrien Samson\, Healthcare Biotechnology Manager\, EuropaBio\n\n\n\n\n\nInvitation Only Event URL:https://www.europabio.org/event/europabio-patient-bioforum-2022-toward-a-common-understanding-of-unmet-medical-needseuropabio-patient-bioforum-2022/ CATEGORIES:EuropaBio,Healthcare Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/11/Patient-BioForum-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20221130T083000 DTEND;TZID=Europe/Brussels:20221130T094500 DTSTAMP:20260726T164841 CREATED:20221103T154442Z LAST-MODIFIED:20221114T101045Z UID:5462-1669797000-1669801500@www.europabio.org SUMMARY:EFIB 2022 Vilnius Statement wider launch DESCRIPTION:Industrial Biotechnology for a sustainable society: a focus for 2023 and beyond Industrial biotechnology and biomanufacturing are recognised as being part of the response to some of today’s pressing global challenges. Delivering on EU Green Deal objectives whilst strengthening resilience and independence of European industries is increasingly critical.  \n\n\n\nThe inaugural EFIB Statement of October 2021 created a baseline for industrial biotechnology and bioeconomy vision in policy\, regulatory and landscape development. The EuropaBio’s EFIB Vilnius Statement of 2022 evolves to address this long-term vision and ambition within the context of challenges and needs over the next 12 months.  \n\n\n\nWe invite you to join us for a discussion on the role and potential of enabling technologies in the EU green transition\, with a focus on priorities for the shorter term and building up to the longer term.   \n\n\n\n \n\n\n\n\nInvitation Only Event URL:https://www.europabio.org/event/efib-2022-vilnius-statement-wider-launch/ CATEGORIES:EFIB,EuropaBio,Industrial Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/11/Vilnius-Statement-Event-600-×-260px-1-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20220929T140000 DTEND;TZID=Europe/Brussels:20220929T150000 DTSTAMP:20260726T164841 CREATED:20220830T122553Z LAST-MODIFIED:20220922T103100Z UID:5064-1664460000-1664463600@www.europabio.org SUMMARY:European Biotech Week 2022: At the cutting edge of biotechnology for cardiovascular diseases: A World Heart Day special edition webinar DESCRIPTION:Healthcare Biotechnology has the potential to transform how healthcare is delivered to patients\, both in terms of innovative treatments\, but also via use of innovative prevention\, screening\, and testing measures. \n\n\n\nDuring this webinar\, which marks World Heart Day\, speakers will discuss how biomarker testing for genetically inherited risk factors for cardiovascular diseases is opening up new frontiers in healthcare\, and saving lives across the world. \n\n\n\nFeaturing speakers from the patient community\, research and academia\, and industry\, the conversation will also address the need to translate guidelines into practice\, and will end with an interactive Q&A. \n\n\n\nSpeakers: \n\n\n\nMarius Geanta\, Trustee and the Chair of the Policy Advisory Committee\, FH EuropeLena Lymperopoulou\, Global Policy Head Therapeutic Area Cardiovascular\, NovartisFlorian Kronenberg\, Full Professor and Head of the Institute of Genetic Epidemiology\, Medical University of InnsbruckJamie Wilkinson\, Healthcare Biotechnology Director\, EuropaBio\n\n\n\n\nREGISTER NOW URL:https://www.europabio.org/event/european-biotech-week-2022-hc/ CATEGORIES:Biotech Week,EuropaBio,Healthcare Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/09/Europabio-HC.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20220927T140000 DTEND;TZID=Europe/Brussels:20220927T150000 DTSTAMP:20260726T164841 CREATED:20220830T105859Z LAST-MODIFIED:20220914T134233Z UID:5054-1664287200-1664290800@www.europabio.org SUMMARY:European Biotech Week 2022: Innovative technologies in the EU green transition – spotlight on industrial biotechnology DESCRIPTION:Industrial Biotechnology-derived products offer significant potential for contributing to overcoming many EU socio-economic and environmental challenges. It is not a new sector. On the contrary\, for thousands of years the power of microbes has been harnessed in food production and beverages. In the past century\, the applications for IB have expanded greatly with IB now providing living microorganisms and fermentation products that are used in sectors as diverse as food and feed\, agriculture\, detergents\, paper and pulp\, textiles\, fuels\, bioenergy\, and specialty chemicals. \n\n\n\nResearch and innovation are key drivers to accelerate the green transition. Indeed\, the EU Green Deal notes that “New technologies\, sustainable solutions and disruptive innovation are critical to achieve the objectives of the European Green Deal”. In this context\, a range of solutions will be needed. Alternatives to fossil-based products\, improved resource efficiency of industrial processes\, innovative food and feed are all targets where industrial biotechnology and bioeconomy innovation can deliver. \n\n\n\nThis webinar will discuss innovative solutions that can contribute towards the green transition\, with a focus on industrial biotechnology. It will zoom in on products of IB and their benefits and challenges\, also linking to the EU GMO regulatory framework and recent developments on new genomic techniques. \n\n\n\nSpeakers: \n\n\n\nMarc Leclerc\, Senior Regulatory Affairs Advisor\, NovozymesRachel Melnick\, Senior Scientific Program Manager\, Agriculture & Food Systems InstituteHans Genee\, Co-Founder and CSO\, Biosyntia\n\n\n\n\nREGISTER NOW URL:https://www.europabio.org/event/european-biotech-week-2022-ib/ CATEGORIES:Biotech Week,EuropaBio,Industrial Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/09/Europabio-IB.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20220926T140000 DTEND;TZID=Europe/Brussels:20220926T151500 DTSTAMP:20260726T164841 CREATED:20220830T121819Z LAST-MODIFIED:20220923T072206Z UID:5060-1664200800-1664205300@www.europabio.org SUMMARY:European Biotech Week 2022: Biotechnology for society\, sustainability and economies – transformative science for a changing world DESCRIPTION:The 2022 European Biotech Week from EuropaBio opens with a look at how biotechnology is at the centre of Europe’s transformation to a healthy\, sustainable and competitive economy and society. \n\n\n\nJoin our Board Members from across Europe’s biotechnology spectrum to learn about biotech in action and its benefits in our every day lives\, as well as how it supports employment\, economic development and Europe’s place in the world. \n\n\n\nSpeakers: \n\n\n\nPatricia Malarkey\, Global Chief Innovation Officer\, DSMStefan Buchholz\, Senior VP R&D Nutrition and Care\, EvonikTom Bols\, Head of Government Affairs and Patient Advocacy\, PTC TherapeuticsAnnemeik Verkamman\, Managing Director\, HollandBio\n\n\n\n\nREGISTER NOW URL:https://www.europabio.org/event/european-biotech-week-2022-biotechnology-for-society-sustainability-and-economies-transformative-science-for-a-changing-world/ CATEGORIES:Biotech Week,EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/09/Events-Template-600-×-200px.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20220602T150000 DTEND;TZID=Europe/Brussels:20220602T161500 DTSTAMP:20260726T164841 CREATED:20220510T072627Z LAST-MODIFIED:20220517T120255Z UID:4513-1654182000-1654186500@www.europabio.org SUMMARY:Rare Conversations 2022! DESCRIPTION:Managing uncertainties in rare disease innovation\n\n\n\n\n\nJoins us for the new episode of Rare Conversations 2022! \n\n\n\nThe second episode of Rare Conversations 2022 will build on the previous Conversation about game-changing opportunities in rare disease R&D. In the first episode\, different experts convened on the existence of opportunities in rare diseases\, that still face obstacles that need to be addressed. This event is meant to discuss and propose solutions on: “Managing uncertainties in rare disease innovation” URL:https://www.europabio.org/event/rare-conversations-2022-2/ CATEGORIES:EuropaBio,External,Healthcare Biotech ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2022/05/Event-Banners-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20211213T140000 DTEND;TZID=Europe/Brussels:20211213T150000 DTSTAMP:20260726T164841 CREATED:20211116T143909Z LAST-MODIFIED:20211216T093602Z UID:3429-1639404000-1639407600@www.europabio.org SUMMARY:EuropaBio 25th Anniversary | mRNA: A voyage of discovery and celebration DESCRIPTION:The existence of messenger(m) RNA was hypothesized early in the days of DNA breakthroughs in the 1960s\, and research from the 1990s started to reveal its potential as a therapeutic tool. \n\n\n\nmRNA became a household name in 2020 and 2021 as arguably the most important global breakthrough of recent years\, with its ability to create a specific proteins underpinning vaccine development in response to Covid-19.EuropaBio is delighted to host the final event of its 25th Anniversary programme with a focus on the story of mRNA. Its first steps into commercial development\, challenges to bring a vaccine to millions of people and life beyond Covid – the destination for mRNA in oncology and other significant health applications. \n\n\n\nWe bring together protagonists from across the spectrum\, including:• Ingmar Hoerr\, CureVac Founder and holder of the first patents associated with mRNA• Stephen Lockhart\, Head of EU/AP Vaccines Clinical R&D at Pfizer• Dhaval Patel\, Senior Manager\, Manufacturing & Technology\, Catalent Biologic URL:https://www.europabio.org/event/europabio-25th-anniversary-mrna-a-voyage-of-discovery-and-celebration/ CATEGORIES:EuropaBio,Healthcare Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/11/Event-Banners-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20211130T140000 DTEND;TZID=Europe/Brussels:20211130T151500 DTSTAMP:20260726T164841 CREATED:20211103T141708Z LAST-MODIFIED:20211119T105146Z UID:3401-1638280800-1638285300@www.europabio.org SUMMARY:EFIB 2021 | Vienna Statement Launch DESCRIPTION:The ‘EFIB 2021 Vienna Statement’ marked the launch of an annual call to action from EuropaBio members\, with policy asks and actions critical in the short term for Europe’s delivery of a bioeconomy. \n\n\n\nDeveloped through 2021 and published at EFIB in Vienna\, the statement includes:• Next generation Europe: An urgent call to action• Industrial biotechnology: Proving its value to society\, environment and economy• The clock is ticking for European climate and competitive ambitions• Time is now – EFIB Vienna Statement requests for modernisation of regulation and policy\, Education and awareness and financing innovation \n\n\n\nModerator: \n\n\n\n• Dr Claire Skentelbery\, Director General\, EuropaBio \n\n\n\nSpeakers: \n\n\n\n• Stefan Buchholz\, Senior Vice President R&D Nutrition & Care\, Evonik \n\n\n\n• Elke Duwenig\,  Senior Biotechnology Expert Regulatory / Public & Government Affairs\, Nutrition & Health\, BASF \n\n\n\n• Jim Philp\, Science and Technology Analyst\, OECD \n\n\n\n• Video message by Simone Schmiedtbauer\, Member of the European Parliament\, Group of the European People’s Party\, Austria \n• Video message by Virginijus Sinkevičius\, European Commissioner for Environment\, Oceans and Fisheries \n\n\n\nWe invite you now to join us for the wider launch of the EFIB Vienna Statement – to set the challenge for Europe and discuss what this means for policy\, regulation\, investment and innovation. \n\n\n\nJoin us on 30 November at 14:00 CET and be part of the conversation in the 12 months until the next EFIB conference in Vilnius\, Lithuania\, October 2022. \n\n\n\n\nRegister Here URL:https://www.europabio.org/event/efib-2021-vienna-statement-launch/ CATEGORIES:EFIB,EuropaBio,Industrial Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/11/Event-Banners-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20211025T130000 DTEND;TZID=Europe/Brussels:20211025T141500 DTSTAMP:20260726T164841 CREATED:20210916T104948Z LAST-MODIFIED:20211008T103436Z UID:3115-1635166800-1635171300@www.europabio.org SUMMARY:EuropaBio 25th Anniversary | Healthy planet\, Healthy people DESCRIPTION:At the time of the 25th Anniversary of EuropaBio\, we would like to look to the future and the green transition that will shape healthcare for us all. \n\n\n\nThis open webinar aims at kicking off the discussion on pathway for green transition in the biopharmaceutical ecosystem. This biopharmaceutical ecosystem has a complex and resource intensive profile\, from research\, to manufacture through to use and disposal of highly regulated therapeutics. \n\n\n\nChange is Now\, with companies investing in long term product and process design for carbon neutrality and circularity.  Join us to hear from pharma\, sustainable pharmaceutical engineering\, policy makers\, consumers and the European Commission on the priorities\, actions and outcomes to ensure that healthy people go hand in hand with a healthy planet. \n\n\n\nModerator: \n\n\n\nDr Claire Skentelbery\, Director General\, EuropaBio\n\n\n\nSpeakers: \n\n\n\nCarmen Laplaza\, Head of Unit\, Health Innovations and Ecosystems\, DG Research and Innovation\n\n\n\nMontserrat Montaner\, Chief Sustainability Officer\, Novartis\n\n\n\nJutta Paulus\, Member of the European Parliament\, Group of the Greens\, Germany\n\n\n\nDr Wouter De Soete\, Manager Centre of Excellence in Sustainable Pharmaceutical Engineering & Manufacturing\, University of Ghent\n\n\n\nKristin Schreiber\, Director\, Directorate Ecosystems: Chemicals\, Food\, Retail\, Health\, DG Grow\, European Commission\n\n\n\n\n\nREGISTER HERE URL:https://www.europabio.org/event/europabio-25th-anniversary-healthy-planet-healthy-people/ CATEGORIES:EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/09/Event-Banners-1.png END:VEVENT END:VCALENDAR